Paxlovid (nirmatrelvir-ritonavir) is efficient at stopping hospitalization and demise from COVID-19, however few folks use it. A paper by SteelFisher et al. (2024) surveyed 1,430 American adults to seek out out why. Their survey revealed sufferers had a ignorance of the therapy in addition to misinformation in regards to the therapy (amongst those that had been conscious of it). Particularly:
A majority of respondents (85 %) had no or low consciousness of Paxlovid, together with 31 % who had by no means heard of it. Even amongst those that had been conscious of the drug, many held misperceptions about its effectiveness (39 %), antagonistic results (86 %), and requisite timing (61 %) that would result in underuse. Decrease consciousness and misperceptions had been extra widespread amongst medically weak and deprived populations who may profit most from Paxlovid entry, together with adults unvaccinated in opposition to COVID-19, these with decrease ranges of schooling, and Black and Hispanic or Latino adults.
You possibly can learn the total paper right here.
